Vermont Senators Propose Expansion of Psychedelic Therapy Advisory Group
LOS ANGELES- A group of Vermont state senators has introduced Senate Bill 106 (S.106), aiming to extend and expand the scope of the existing Psychedelic Therapy Advisory Working Group. The bill proposes to continue the group’s tenure, add new members, and broaden its mandate to further explore the potential of psychedelic-assisted therapies within the state.
Background
In 2024, the Vermont Legislature established the Psychedelic Therapy Advisory Working Group through Act 126. The group’s mission was to review existing research on the benefits and risks of clinical psychedelic-assisted treatments and to assess the feasibility of a state program permitting health care providers to administer such therapies.
The working group released its report in November 2024, indicating a cautious stance toward immediate implementation of psychedelic therapies. Members highlighted the need for more comprehensive research and data before recommending the establishment of a state-sanctioned program.
Provisions of S.106
The newly introduced bill seeks to:
Extend the Working Group’s Tenure: Allow the group to continue its research and deliberations beyond the original timeframe.
Expand Membership: Include additional members with expertise in areas such as psychedelic treatment, mental health, legal affairs, and public representation.
Broaden Scope: Task the group with ongoing reviews of the latest research on clinical psychedelic-assisted treatments, monitor legislative developments in other states, consider harm reduction training and education, and propose pilot projects for psilocybin-assisted therapies, particularly for serious illnesses and end-of-life care.
S.106 has been referred to the Senate Committee on Health and Welfare for further consideration. If enacted, the expanded working group would continue its efforts to provide informed recommendations on the potential integration of psychedelic therapies into Vermont’s healthcare system